Claims for Patent: 4,264,573
✉ Email this page to a colleague
Summary for Patent: 4,264,573
| Title: | Pharmaceutical formulation for slow release via controlled surface erosion |
| Abstract: | A pharmaceutical composition in tablet form for oral administration comprises: (a) 30-90% by weight of an active ingredient having a water solubility (20.degree. C.) of about 1/10-1/500 (w/w); (b) 1-40% by weight of an excipient which is pharmaceutically acceptable in oral tablets and which has a water solubility (20.degree. C.) of about 1/1-1/20 (w/w); (c) 0-20% by weight of a binder which is pharmaceutically acceptable in oral tablets; (d) 0-50% by weight of an excipient which is pharmaceutically acceptable in oral tablets and which has a water solubility (20.degree. C.) of about 1/1-1/5 (w/w); (e) 0.5-5% by weight of a die wall lubricant pharmaceutically acceptable in oral tablets; (f) 0-5% by weight of a surface active agent pharmaceutically acceptable in oral tablets; and (g) 0-1.0% by weight of a disintegration agent pharmaceutically acceptable in oral tablets; whereby the active ingredient has a slow in vivo release rate due to controlled surface erosion of the tablet. |
| Inventor(s): | Powell; David R. (Baudette, MN), Patel; Vithal K. (Baudette, MN) |
| Assignee: | Rowell Laboratories, Inc. (Baudette, MN) |
| Application Number: | 06/040,789 |
| Patent Claims: |
1. A pharmaceutical composition in tablet form for oral administration consisting essentially of
(a) 70-80 wt.% of lithium carbonate; (b) 5-15 wt.% of an excipient which is pharmaceutically acceptable in oral tablets and which has a water solubility (20.degree. C.) of about 1/1-1/20 (w/w); (c) 2-7 wt.% of a binder which is pharmaceutically acceptable in oral tablets; (d) 5-15 wt.% of an excipient which is pharmaceutically acceptable in oral tablets and which has a water solubility (20.degree. C.) of about 1/1-1/5 (w/w); (e) 0.9-3.3 wt.% of a dye wall lubricant pharmaceutically acceptable in oral tablets; (f) 0.1-0.2 wt% of a surface active agent pharmaceutically acceptable in oral tablets; and (g) 0.15-0.35 wt.% of a disintegration agent pharmaceutically acceptable in oral tablets; whereby the active ingredient has a slow zero order in vivo release rate and a plasma concentration/time curve of substantially the same shape as that of FIG. 1, due to controlled surface erosion of the tablet. 2. The pharmaceutical composition of claim 1 consisting essentially of: 70-80 wt.% of lithium carbonate; 5-15 wt.% of sodium chloride; 2-7 wt.% of polyvinylpyrrolidone; 5-15 wt.% of sorbitol; 0.9-3.3 wt.% of calcium stearate; 0.1-0.2 wt.% of sodium lauryl sulfate; and 0.15-0.35 wt.% of sodium starch glycolate. 3. The pharmaceutical composition of claim 2 consisting essentially of the following approximate amounts of ingredients: 300 mg of lithium carbonate; 40 mg of sodium chloride; 15 mg of polyvinylpyrrolidone; 9.4 mg of calcium stearate; 0.6 mg of sodium lauryl sulfate; 40 mg of sorbitol; and 1 mg of sodium starch glycolate. 4. The pharmaceutical composition of claim 1, 2 or 3 which is in the form of a tablet of a hardness of 5-20 kg. |
